Kennedy Ferruggia, Assistant Editor

RSV vaccines were 80% effective in preventing hospitalization, ICU admission, and death among adults aged 60 years and older.

Clesrovimab reduced RSV-associated hospitalizations and RSV-associated lower respiratory infection hospitalizations by more than 84% and 90% in preterm and full-term infants, respectively.

Less than 16% of high-risk lung cancer individuals have heard or discussed lung cancer screenings with a health care provider.

ELA026 is a first in class antibody therapy targeting signal regulatory proteins.

The randomized, placebo-controlled RESCUE phase 3 trial assessed clofutriben among individuals with ACTH-dependent endogenous Cushing syndrome.

Low levels of vitamin D was linked with increased obstructive Apnea-Hypopnea Index scores.

Further efforts may be required to urge eligible members of the public to get screened for lung cancer.

Findings suggest further need to educate the public on receiving an indicated vaccine as we approach peak respiratory syncytial virus (RSV) season.

The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.

Islatravir in combination with lenacapavir could become the first weekly oral HIV treatment.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

Findings highlight the need for health care providers to continue to educate patients on the risk of scurvy, ensuring proper vitamin C intake.

Treatment with valacyclovir for a year decreased the risk of new or worsening eye disease by 26%.

The approval marks Abrysvo as the first and only RSV vaccine designated for adults younger than 50 that are at increased risk for LRTD.

The connection of F proteins could help destabilize the virus prior to infection of the next host.

Increasing serum vitamin B12 before and after the onset of pancreatitis reduced the severity of the condition.

The results emphasize the need for pharmacists and health care providers to further educate patients about receiving recommended immunizations.

Gepotidacin could be first-in-class oral antibiotic treatment approved for uUTIs in over 20 years.

The trial met its primary endpoint of event-free survival, furthering treatment options for resected, locally advanced head and neck squamous cell carcinoma.

Female and older patients had a greater incidence of herpes zoster ophthalmicus and were more likely to develop ocular complications.

As the first dual neurokinin-1 and 3 receptor antagonist, elinzanetant could provide benefit for women suffering from vasomotor symptoms.

A single dose RSV vaccine per year can offer optimal protection against 3 full RSV seasons.

The addition of high-dose vitamin D3 to standard treatment did not delay the progression of cancer compared with the standard dose of vitamin D3.

Setrusumab could offer a rapid and clinically meaningful decrease in fracture rate in individuals with osteogenesis imperfecta.

The Inflation Reduction Act's zero cost-sharing policy resulted in significant increases in shingles vaccines dispensed to individuals under Part D, compared with those who are commercially insured.

Pharmacists and health care providers can counsel around vitamin D supplements and natural intake to increase a child’s vitamin D consumption.

RSV vaccination could be cost-effective among adults 60 years and older, with the ability to decrease vaccine costs and sustain efficacy.

Navenibart was developed to aid treatment of hereditary angioedema (HAE) to provide swift and sustained HAE attack prevention through administration every 3 to 6 months.

Adults with underlying medical conditions, resulting in an increased risk of respiratory syncytial virus disease are more likely to be cost-effective than general age-based strategies.